Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus.
Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus.
复制标题
DOI：
10.1002/adtp.202000203
复制
发表时间：
2021-03
影响因子：
4.6
通讯作者：
Minko T
中科院分区：
文献类型：
--
作者：
Majumder J;Minko T
用于治疗肺病的治疗剂的全身递送具有若干限制，包括递送的有效载荷的器官分布差，活性物质在肺中的累积相对较低，以及严重的不良副作用。相比之下，基于纳米载体的治疗剂提供了广泛的机会，这是由于它们能够包封具有不同水溶性的物质，运输不同类型的货物，将治疗剂特异性靶向死亡的器官、细胞或细胞器，从而限制不良副作用并增加治疗的功效。此外，许多纳米治疗剂可以通过吸入局部递送到肺部，避免体循环。此外，基于纳米级的递送系统可以是多功能的，同时执行若干任务，包括诊断、治疗和抑制细胞对治疗的抗性。纳米级递送系统改善了常规治疗剂的临床功效，允许用于治疗难以治疗或对治疗具有内在或获得性抗性的呼吸道疾病的新方法。本文综述了基于纳米载体的治疗剂的最新进展，用于局部和靶向递送药物、核酸和成像剂，用于诊断和治疗各种疾病，如癌症、囊性纤维化和冠状病毒。特异性地将纳米治疗剂靶向递送至患病肺、肺细胞和/或特定细胞器通过增强治疗功效和限制严重不良副作用而提供优于全身递送的明显优势。基于纳米尺度的系统可以运输各种类型的有效载荷，同时执行几项不同的任务，并在诊断，治疗和抑制细胞抗性方面发挥多种功能。
Systemic delivery of therapeutics for treatment of lung diseases has several limitations including poor organ distribution of delivered payload with relatively low accumulation of active substances in the lungs and severe adverse side effects. In contrast, nanocarrier based therapeutics provide a broad range of opportunities due to their ability to encapsulate substances with different aqueous solubility, transport distinct types of cargo, target therapeutics specifically to the deceased organ, cell, or cellular organelle limiting adverse side effects and increasing the efficacy of therapy. Moreover, many nanotherapeutics can be delivered by inhalation locally to the lungs avoiding systemic circulation. In addition, nanoscale based delivery systems can be multifunctional, simultaneously carrying out several tasks including diagnostics, treatment and suppression of cellular resistance to the treatment. Nanoscale delivery systems improve the clinical efficacy of conventional therapeutics allowing new approaches for the treatment of respiratory diseases which are difficult to treat or possess intrinsic or acquired resistance to treatment. The present review summarizes recent advances in the development of nanocarrier based therapeutics for local and targeted delivery of drugs, nucleic acids and imaging agents for diagnostics and treatment of various diseases such as cancer, cystic fibrosis, and coronavirus. Targeted delivery of nanotherapeutics specifically to diseased lungs, pulmonary cells, and/or specific organelles offers distinct advantages over systemic delivery by enhancing efficacy of the treatment and limiting severe adverse side effects. Nanoscale based systems can transport various types of payload, simultaneously carry out several distinct tasks and perform multiple function in diagnosis, treatment, and suppression of cellular resistance.
登录
查看更多内容
影响因子：
13.3
作者：
Chen, Alex M.;Zhang, Min;Wei, Dongguang;Stueber, Dirk;Taratula, Oleh;Minko, Tamara;He, Huixin
通讯作者：
He, Huixin
影响因子：
5.4
作者：
Betigeri, Seema;Zhang, Min;Garbuzenko, Olga;Minko, Tamara
通讯作者：
Minko, Tamara
影响因子：
17.1
作者：
Chen, Alex M.;Taratula, Oleh;Wei, Dongguang;Yen, Hsin-I;Thomas, Thresia;Thomas, T. J.;Minko, Tamara;He, Huixin
通讯作者：
He, Huixin
影响因子：
50.5
作者：
Berry, G;Billingham, M;Martin, FJ
通讯作者：
Martin, FJ
DOI：
10.1007/s41061-017-0128-5
发表时间：
2017-04
期刊：
Topics in current chemistry (Cham)
影响因子：
--
作者：
Amreddy N;Babu A;Muralidharan R;Munshi A;Ramesh R
通讯作者：
Ramesh R